Kristine

I, Kristine Whorlow, nominated by the Australian Government, residing in _Melbourne, Australia, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I retired as the CEO of the National Asthma Council Australia in 2017. My responsibilities included producing the national treatment guidelines for asthma and implementing these through an extensive national program of primary care health professional education as well as conducting national promotional campaigns to promote community education on asthma for patients and health professionals. I was also responsible for conducting outreach education activities in Asia Pacific. I am currently the First Vice President of the Global Airways and Allergy Patient Platform (GAAPP), the only global patient organisation in this field whose main role is to support existing and emerging patient organisations dedicated to patient support and advocacy in airways disease and allergy. I have recently joined the advisory board of a new medical respiratory device company, Respia.
3. My responsibilities on the board of GAAPP and the advisory board of Respia include general advice on governance, financial management, strategic planning, communication and the respiratory field.
4. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
5. My interests , and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   • Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions: none relevant.
   • Government advice and other policy development: I occasionally provide general advice to the National Asthma Council Australia on some of the issues considered by MCTOC, e.g. GWP of inhalers, based on MCTOC’s published reports.
   • Paid research activities, fellowships or grants: none.
   • Other interests: none relevant.
6. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is my personal cost.
7. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
8. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
9. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
10. I understand that this DOI will expire no later than one year after I have signed it.

Name: Kristine Whorlow AM
Date: April 21, 2021